Personalized glioblastoma vaccine shows safety and survival promise in phase 1 trial
By
Washington U. in St. Louis
19h ago· 8 min readenNews
85/100
Golden Brown
Bagelometer↗
Master baker tier. Every paragraph earns its place on the tray.
Score85TypenewsSentimentpositive
Summary
A phase 1 clinical trial at Siteman Cancer Center found that a personalized vaccine for glioblastoma, an aggressive brain cancer, is safe and shows potential to improve patient outcomes. The vaccine caused no serious side effects and extended overall survival compared to historical outcomes from standard treatments. One patient remains recurrence-free nearly five years after treatment.
Key quotes
· 1 pulledWe are extremely encouraged by these results.
A new clinical trial has found that a personalized vaccine to treat glioblastoma is safe and could potentially improve outcomes.
